Licensing status

Publication and contact information

Endocrine/metabolic disease


Glucagon receptor (GCGR)

In vitro and mouse studies identified an allosteric GCGR antibody that could help treat type 2 diabetes. In vitro, an allosteric anti-GCGR antibody bound to and inhibited activation of GCGR. In a mouse model of diabetes, the allosteric antibody decreased blood glucose levels compared with no treatment and improved glucose tolerance. Next steps could include testing the antibody in additional diabetes models.
Ligand Pharmaceuticals Inc., Isis Pharmaceuticals Inc. and Eli Lilly and Co. have anti-GCGR programs in Phase I or II trials to treat diabetes.

SciBX 6(48); doi:10.1038/scibx.2013.1389
Published online Dec. 19, 2013

Patent and licensing status unavailable

Mukund, S. et al. J. Biol. Chem.; published online Nov. 4, 2013;
Contact: Bernard B. Allan, Genentech Inc., South San Francisco, Calif.
Contact: Christopher M. Koth,
same affiliation as above